Nicholas Colatrella
Optometrist · Sartell, MNNPI 1467507475
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $58,565 of the $84,400 with a category attached, or 69.4%. Katena Products, Inc. (dba Corza Medical) accounts for 66.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $23,411 and has fallen 95.3% since, to $1,100 in 2025. Among optometrist clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 83 payments — averaging $1016.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Katena Products, Inc. (dba Corza Medical)$56K
- Dompe US, Inc.$15K
- Surgical Specialties Corporation (US), Inc. (dba Corza Medical)$8K
- AbbVie$3K
- Biotissue Holdings Inc.$1K
- Oyster Point Pharma, Inc.$720
- plus $766 from 11 others
What the payments were for
- Royalty or licence$3,7204%
- Consulting fees$19,28223%
- Speaking & faculty fees$58,56569%
- Travel & lodging$1,0021%
- Food & beverage$1,8312%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Katena Products, Inc. (dba Corza Medical) | 6 | $56,054 |
| Dompe US, Inc. | 24 | $14,762 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 4 | $8,034 |
| AbbVie(2 entities) | 7 | $2,815 |
| Biotissue Holdings Inc. | 8 | $1,248 |
| Oyster Point Pharma, Inc. | 7 | $720 |
| Sun Pharmaceutical Industries Inc. | 5 | $206 |
| Alcon | 6 | $104 |
| The Cameron-ehlen Group, Inc. | 1 | $88 |
| LKC Technologies, Inc. | 2 | $86 |
| Glaukos Corporation | 2 | $70 |
| Novartis | 4 | $59 |
| Tarsus Pharmaceuticals, Inc. | 2 | $56 |
| Coopervision Inc. | 2 | $34 |
| Harrow Eye, LLC | 1 | $26 |
| Shire North American Group Inc | 1 | $19 |
| Kala Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$84,400 in reported general payments places this provider in the 95th percentile of 826 optometrist providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 13 | $627,187 |
| RestasisCyclosporine | 69 | $60,949 |
| Cyclosporine | 36 | $18,251 |
| XiidraLifitegrast | 12 | $16,466 |
| MieboPerfluorohexyloctane/Pf | 20 | $14,251 |
| LumiganBimatoprost | 21 | $13,173 |
| TyrvayaVarenicline Tartrate | 13 | $10,949 |
| RhopressaNetarsudil Mesylate | 24 | $9,740 |
| Prednisolone Acetate | 65 | $2,910 |
| Timolol Maleate | 14 | $1,494 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 42 | $1,171 |
| Latanoprost | 59 | $1,072 |
| Ofloxacin | 17 | $378 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $14,762 | $627,18713 claims |
| AbbVieRestasis, Lumigan | $2,815 | $74,12290 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $720 | $10,94913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 826 optometrist providers in Minnesota.
Other optometrist in Sartell
- Trevor FossoSartell$45K
- Kelly FreeseSartell$6K
- Jacob LangStillwater$264K
- Britt GustafsonEden Prairie$236K
- Gina WesleyMedina$232K
- Mathew WalkerAlexandria$43K
- Joshua HanenMinneapolis$40K
- Zachary HollandEdina$36K
- Patrick WellikApple Valley$15K
- Paul HammondCoon Rapids$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.